Search

Displaying results 1791 - 1800 of 10000 in total
  1. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    and offset of action. … Cangrelor was approved by the FDA in June 2015 for intravenous application.

  2. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic … and approval of just 61 days.

    Synonyms: DB-OTO
  3. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

  4. Drug

    Fluoxetine

    go.drugbank.com/drugs/DB00472
    ApprovedInvestigationalVet approved

    [A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies

    Mixtures: PISAURIT FONCategories: Metabolic Side Effects of Drugs and Substances, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Ditiocarb zinc

    go.drugbank.com/drugs/DB14193
    Approved

    Ditiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen. Sensitivity to ditiocarb zinc may be identified with a clinical patch test.

    Synonyms: Zinc N,N-diethyldithiocarbamateCategories: Compounds used in a research, industrial, or household setting, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  6. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. … This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.

    Categories: Increased Diuresis at Loop of Henle, Non Potassium Sparing Diuretics
  7. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials … [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression

  8. Drug

    Tafluprost

    go.drugbank.com/drugs/DB08819
    Approved

    Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012. … A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

    Mixtures: TAPCOM-S ophthalmic solution 15 micrograms/ml + 5 mg/ml, solution in single-dose container
  9. Drug

    Attapulgite

    go.drugbank.com/drugs/DB01574
    ApprovedVet approvedWithdrawn

    Attapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. … When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma